- AstraZeneca
- 14 July 2025 07:35:12
Source: Sharecast
The drug, which was tested in patients with uncontrolled or treatment-resistant hypertension over 12 weeks, demonstrated a “statistically significant and clinically meaningful reduction” of systolic blood pressure compared with the placebo, the pharma giant said.
Baxdrostat is AstraZeneca's first-in-class aldosterone synthase inhibitor that targets the hormone which drives elevated blood pressure and increased cardiovascular and renal risk.
According to AstraZeneca, around 50% of hypertensive patients in the US who are on multiple treatments do not have their blood pressure under control, and uncontrolled hypertension can lead to a higher risk of heart attack, stroke, heart failure and kidney disease.
Sharon Barr, executive vice president of BioPharmaceuticals R&D at AstraZeneca, said "we are very excited" with the results from the BaxHTN trial.
"These findings provide compelling evidence of baxdrostat’s potential to address a critical unmet need by targeting aldosterone dysregulation, bringing a novel mechanism to a field that has seen little innovation in over two decades.”